Citi Pharma profit climbs 7% in FY25, unveils 35% cash dividend

October 2, 2025 (MLN): Citi Pharma Limited (PSX: CPHL) reported a profit after tax of Rs892.0 million for the year ended June 30, 2025, showing a 7.0% increase compared to Rs833.5m in FY24.

Earnings per share rose to Rs3.90 from Rs3.65 last year. Alongside the results, the company declared a cash dividend of Rs3.5 per share (35%).

Net sales grew 6.0% year-on-year to Rs13.15bn, supported by higher demand, while the cost of sales increased at a slower pace of 2.9% to Rs11.14bn.

Consequently, gross profit expanded 27.2% to Rs2.02bn against Rs1.59bn in FY24, with the gross margin improving to 15.3% from 12.8% a year earlier.

Administrative expenses rose 8.8% to Rs222.1m, while marketing and distribution expenses increased 8.4% to Rs191.2m.

Despite rising expenses, operating profit advanced 33.1% year-on-year to Rs1.60bn, compared to Rs1.21bn last year.

Financial charges climbed 9.9% to Rs329.7m, while other income dropped sharply by 59.5% to Rs198.3m. Other expenses inched up 3.6% to Rs118.3m.

Profit before tax improved 6.0% to Rs1.35bn from Rs1.28bn in FY24. Tax expense stood at Rs462.5m, up 4.1% year-on-year.

The company concluded FY25 with a net profit of Rs892.0m, maintaining earnings growth despite a significant decline in other income.

Net profit margin stood at 6.8%, broadly stable compared to the prior year.

Copyright Mettis Link News